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ABSTRACT: A theory for deriving drug-DNA site binding constants from footprinting data is presented.

Plots of oligonucleotide concentration, as a function of drug concentration, for various cutting positions on
D N A are required. It is assumed that the rate of cleavage at each nucleotide position is proportional to
the concentration of enzyme at that nucleotide and to the probability that the nucleotide is not blocked by
drug. The probability of a nucleotide position not being blocked is calculated by assuming a conventional
binding equilibrium for each binding site with exclusions for overlapping sites. The theory has been used
to evaluate individual site binding constants for the antiviral agent netropsin toward a 139 base pair restriction
fragment of pBR-322 DNA. Drug binding constants, evaluated from footprinting data in the presence of
calf thymus D N A and poly(dGdC) as carrier and in the absence of carrier DNA, were determined by
obtaining the best fit between calculated and experimental footprinting data. Although the strong sites
on the fragment were all of the type (T-A),, the value of the binding constant was strongly sequence dependent.
Sites containing the dinucleotide sequence 5'-TA-3' were found to have significantly lower binding constants
than those without this sequence, suggesting that an adenine-adenine clash produces a D N A structural
alteration in the minor groove which discourages netropsin binding to DNA. The errors, scope, and limitations
associated with the method are presented and discussed.

Footprinting analysis is widely used in studying ligand
binding to DNA. The approach, which utilizes DNA sequencing technology, relies on the ability of a DNA-bound
ligand to inhibit DNA cleavage at its binding site. Since the
initial footprinting studies involving the lac repressor-DNA
interaction (Galas & Schmitz, 1978; Schmitz & Galas 1979),
the method has been used to study a variety of DNA binding
proteins (Johnson et al., 1979; Sakonju & Brown, 1982) as
well as drugs (Dabrowiak, 1983; Lane et al., 1983; Low et al.,
1984; Scamrov & Beabealashvilli, 1983; Van Dyke et al., 1982;
Dervan, 1986) which are capable of binding to DNA in a
sequence-specific manner. The DNA-hydrolyzing enzymes
DNase I and DNase I1 (Drew, 1984), a variety of metal
complexes (Dervan, 1986; Tulluis & Dombroski, 1986; Kuwabara et al., 1986; Ward et al., 1987), alkylating agents
(Ogata & Gilbert, 1979; Ward & Dabrowiak, 1987), and UV
radiation (Becker & Wang, 1984) have been used as probes
to identify ligand binding sites in the footprinting experiment.
Aside from simply revealing the sites of ligand binding,
footprinting analysis has the potential for yielding thermodynamic information on ligand-DNA binding as a function
of sequence. Unlike any other method, it allows evaluation
of individual site binding isotherms and thus provides direct
information on ligand binding constants as a function of the
sequence of DNA bases. Although the bulk of the footprinting
experiments reported to date has been qualitative in nature
and has focused on identifying the interaction sites of DNA
binding ligands, recent elegant work of Ackers and co-workers
(Brenowitz et al., 1986a,b; Senear et al., 1986) demonstrated
that footprinting data can be used to measure thermodynamic
quantities associated with the binding of bacteriophage X CI
repressor to right and left operators.
Although the extension of quantitative footprinting analysis
to small ligand-DNA studies appears straightforward, certain
characteristics of these ligands complicate the extraction of
thermodynamic data. Binding constants of drugs are in most
cases several orders of magnitude less than those of DNA
binding proteins. Thus, the DNA cleaving agents or probes
that are used to score ligand sites may in fact disturb the
0006-2960/88/0427-1198$01.50/0

ligand-DNA interaction that is being measured. A second
important factor associated with drugs concerns their small
size and relatively low binding sequence specificities. Since
they have low specificities, they bind to many sites on DNA,
thereby displacing the probe from DNA. If either the ligand-DNA or the probe-DNA equilibrium were disturbed
during the experiment, the concentrations of oligonucleotides
produced in the footprinting digests would not reflect the true
binding isotherms for the various site loading events taking
place in the system. Finally, it has been shown (Ward et al.,
1987, 1988) that binding of drugs to DNA causes an increase
in DNase I cleavage away from the site of binding. This
enhancement, explained by redistribution of the enzyme on
DNA as binding sites load with drug, needs to be taken into
account in determining binding constants from footprinting
data.
Using the antiviral agent netropsin and a 139-base segment
+
n2Y\

c-NHCH~CONH

/

Netropsir
of pBR-322 DNA, we earlier demonstrated that it is possible
to uncover the individual site loading events on the restriction
fragment with two probes, the enzyme DNase I and a cleaving
cationic manganese porphyrin complex (Ward et al., 1987).
Footprinting plots, showing the rate of cleavage of the probe
as a function of netropsin concentration and sequence, revealed
the sites of strong and weak drug binding and regions of
enhancement on the fragment. In this paper we present the
first quantitative analysis of DNase I footprinting titrations
involving netropsin and show how values may be derived for
site-specific drug binding constants on a DNA restriction
fragment. The method does not require an independent de@ 1988 American Chemical Society

termination of the free drug concentration during the footprinting titration. This quantity, along with the individual site
isotherms and the binding constants, is determined by a
minimization approach involving only the measured footprinting autoradiographic spot intensities and the total drug
concentration. In addition to defining the scope and limitations
of the method, we present new evidence that netropsin can
discriminate between high-affinity sites of the type (A-T), in
a sequence-dependent fashion.

MATERIALS
AND METHODS
The various footprinting studies involving netropsin and the
139 base pair restriction fragment of pBR-322 DNA and data
analysis using linear scanning microdensitometry were as
earlier described (Ward et al., 1987, 1988; Dabrowiak et al.,
1986). Briefly, the total DNA concentration in base pairs for
the experiments involving poly(dGdC) and calf thymus DNA
as carrier was -194 pM (-1 pM fragment and 193 pM
carrier) in a buffer consisting of 50 mM tris(hydroxymethy1)aminomethane hydrochloride (Tris-HCl), 8 mM
MgC12, and 2 mM CaCl, at pH 7.5. The experiments involving only the labeled fragment (no carrier) were carried
out at -1 pM base pairs. All digests, at 37 OC, were terminated early such that -80% of the 139-mer remained uncleaved during the various reactions. The concentration of
DNase I in the experiment involving poly(dGdC) and calf
thymus DNA as carrier was -2 X lo-’ M while the enzyme
concentration for the no-carrier experiment was -2 X lo-*

M.
Each footprinting titration yielded a series of footprinting
plots showing oligonucleotide concentration, as a function of
drug concentration, for 61 sites on the 139-mer. The autoradiographic data were scanned with a linear scanning microdensitometer computer system yielding cross-sectional areas
directly proportioned to oligonucleotide concentration (Dabrowiak et al., 1986). The oligonucleotide concentrations
(areas) ai were corrected for differences in the total extent of
digest for a given reaction. These corrections were usually
<lo% (Ward et al., 1987). The present analysis, aimed at
identifying the binding constants for strong sites of netropsin-DNA interaction, considered only the early loading events
on the 139-mer, so only the lower drug concentrations were
used. Sequence analysis revealed all the strong sites to be of
the type (A-T),.
Densitometric scanning of the autoradiographic data (Dabrowiak et al., 1986) also showed that the total amount of
cleavage on the restriction fragment for all experiments was
constant over the concentration range during which the strong
sites on the fragment were accepting drug. This observation
eliminated the need for correcting the observed footprinting
plots for a shift in the enzymeDNA equilibrium as drug was
added to the system.
The sequence of the fragment studied along with the locations of strong netropsin binding is shown in Figure l . Selected densitometric scans of autoradiographic data are given
in Figure 2. In order to determine individual site binding
constants when overlapping drug sites were involved, it was
necessary to monitor the site loading events at as many points
as possible throughout the overlap region. The observed
footprinting plots and the calculated plots for the most highly
overlapped region of the fragment, having the sequence 5’CAGTTAAATT-3’, positions 53-62, are shown in Figures 3
and 4.
In the case of calf thymus DNA as carrier, the sites at 45,
48, 50, 54, 55, 59, 62, 63, 85, 87, 90, and 154 were used to
monitor strong binding to the fragment while those at 53, 71,

1199

VOL. 27, N O . 4 , 1988

QUANTITATIVE FOOTPRINTING STUDIES

-
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bCGCG4GT4GCAGl4GG4GCCGTGGCbGlGGG4CCl4CG4C~TCCGl4TCCG44CC44T4CGGCC4lGACGGC-5

FIGURE 1: Sequence of the 139 base pair, HindIIIINciI restriction
fragment of pBR-322 DNA. The locations of netropsin binding are
indicated with a solid rectangle (four nucleotides long) on the sequence.
a t position 33.
The fragment is end labeled (32P)
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FIGURE 2: Densitometric scans of selected autoradiographic data
involving netropsin and the 139-mer in the presence of calf thymus
D N A (193 pM base pairs). DNase I alone (-); 7.8 WMnetropsin
(-), the strong sites; 39 pM netropsin (--), the strong and weak sites.

114, and 102 measured the enhancement effect due to redistribution of enzyme on DNA (Ward et al., 1988). Sixteen
netropsin concentrations C in the range 0 IC I8.99 X 10“
M were used in this analysis. There were thus 256 intensities
(oligonucleotide concentrations) to be fitted.
For the experiments using poly(dGdC) as carrier, the sites
used for strong drug binding were 49, 50, 54, 55, 56, 57, 58,
59, 60, 62, 87, 154, and 90; data for sites 102 and 114 were
used to monitor the enhancement. The number of sites, along
with six drug concentrations, in the range 0 IC I4.97 X lo-’
M, gave rise to 90 concentrations to be fitted.
For the carrier-free experiments, the sites monitored were
48, 49, 50, 53, 54, 55, 57, 58, 59, 62, 71, 85, 87, 90, 92, and
98. All showed the effect of drug binding to strong sites except
53, 71, and 98, which monitored enhancement. Since there
were 11 drug concentrations, in the range 0 IC I1.95 X IO-’
M, 176 intensities (oligonucleotide concentrations) were used
in the determination of equilibrium constants. Due to a small
amount of background cleavage observed in the control lanes
of the gel, a “background” densitometric scan was subtracted
from all scans in the carrier-free experiments.
THEORY
The rate of cleavage by DNase I at an exposed phosphodiester linkage of DNA, (rate)i, is governed by expression 1,
(rate), = k:[DNase IIi

(1)

where k : is the cleavage rate constant at the site and [DNase
IIi is the concentration of enzyme at the site. A site on DNA
becomes inaccessible to the enzyme when a drug molecule
binds in such a way as to block the hydrolysis of the phosphodiester linkage. Assuming that (rate)i is then reduced to
0, we write, instead of (l), eq 2, where pi is the probability
(rate), = k:[DNase I]gi

(2)
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FIGURE 3: Observed (0)
and calculated ( 0 )oligonucleotide areas
(concentrations) as a function of the logarithm of the total netropsin
concentration, log C, for the no carrier experiment. The quantity,
x , a correction factor for slight differences in the extent of digest,
and a,, the linearly scaned band area, were determined as earlier
described (Ward et al., 1987; Dabrowiak et al., 1986).
log

that site i is not blocked to the enzyme by bound drug. As
evidence that drug binding totally blocks cleavage, we note
that, for some sites such as 59 and 90, the cleavage rate can
be reduced essentially to 0 by addition of drug.
Since the footprinting digests are terminated early enough
so that one is in the "single-hit" regime, the concentrations
of the various oligonucleotides produced by cleavage are
proportional to the initial cutting rates at the corresponding
sites. Thus, the observed oligonucleotide concentrations reflect
the equilibrium drug binding situation over the sites which
exists before cleavage of DNA takes place (Goodisman &
Dabrowiak, 1985). To predict these concentrations for comparison to experiment, one has to calculate the lpi\as a function
of total drug concentration. In order to do so, other factors
that affect the rate must be considered.
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4: Observed (0)and calculated ( 0 )oligonucleotide areas

(concentrations) as a function of the logarithm of the total netropsin
concentration, log C, for the no-carrier experiment. Quantities x and
ai are defined as in Figure 3.
If, for example, drug binding to one site produces a structural change in DNA within a binding region of another drug
site, i.e., a change in ki,the measured spot intensities associated
with the second site will not reflect the true occupancy of the
site. Although this is not likely to occur for netropsin, which
is known to cause little distortion to DNA (Kopka et al., 1985),
other effects are known to exist.
Correction of Redistribution of DNase I on DNA. The
amount of cleavage at a particular site can be affected by
changes in [DNase IIi as drug loading on the restriction
fragment takes place. Previous studies with netropsin and the
139-mer revealed that the total amount of cleavage on the
fragment remains constant while the strong sites are accepting
drug (Ward et al., 1987, 1988). This shows that the amount
of enzyme on the fragment is constant and that drug binding
simply shifts enzyme to other sites on the fragment. Since drug
binding at one site on a restriction fragment increases [DNase
IIi at other unoccupied sites on the same fragment, the spot
intensities associated with these sites must be corrected for
this enhancement. Since fractional enhancements at almost
all nonbinding sites were observed to be essentially the same,
we take the enhancement effect into account by writing
[DNase IIi = (1

+ ab)[DNase IliO

(3)
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where a is a constant to be determined and b is the amount
of bound drug on a fragment. The enhancement factor of 1
ab applies to binding as well as nonbinding sites.
If it is true that the enhancement arises because drug at one
site shifts enzyme to other sites, without decreasing the amount
of enzyme on the fragment, the factor 1 + ab should be replaced by ( 1 - ab)-’. This would correspond to an even distribution of enzyme over all sites as would occur with a facilitated diffusion mechanism (Winter & von Hipple, 198 1 ) .
As long as ab is not large compared to unity, ( 1 - ab)-’ is
essentially the same as 1 ab. In fact, we have found that
replacing the latter by the former gives rise to only extremely
small changes in the results of our calculations.
The effective concentration of DNase I at a particular site
i in the absence of drug, [DNase IIn, may be incorporated into
the effective rate constant. Since the concentration of a
particular oligonucleotide produced in the footprinting digest
ci is proportional to the initial cleavage rate constant and the
measured area aiis proportional to the oligonucleotide concentration, we have
ai = k g i ( l + ab)
(4)

+

+

where ki = k:[DNase IliOmultiplied by the digest time.
Site Exclusion. The value of piobviously depends on the
drug binding equilibrium constant for site i , Ki, on the drug
concentration, and on the total concentration of restriction
fragment present in the system. Consideration of the structure
of DNase I and the length of netropsin on DNA suggested
that drug binding to site i actually blocks seven or eight sites
from DNase I cleavage (Suck & Oefner, 1986; Ward et al.,
1988). Four sites are blocked due to the length of netropsin
on DNA, while three or four additional sites are blocked due
to the relative orientation between a loop on the enzyme and
its cleavage site. In the following analysis of netropsin footprinting data, it will be evident that the exact size of the
protection region, seven or eight nucleotides, may also depend
on the specific sequence of DNA at which binding is taking
place. However, for the purpose of discussing site exclusion
a protection region of seven is assumed, implying that seven
nucleotide positions can be used to measure Ki. Alternatively,
pidepends on all of the values of Kj, with j between i - 3 and
i 3. By “binding of a drug at site j”, we mean netropsin
occupation of nucleotide positions j , j
1,j
2, and j 3.
For an isolated site i, the binding equilibrium is

+

+

+

+
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centration of any base pair j ) , so be the concentration of
binding regions of the type (A-T), with no drug bound, and
sj be the concentration of binding regions of the type (A-T),
with drug bound at site j within the binding region. Then

and
since the exclusion means that only a totally empty binding
region can bind drug. The probability of having drug bound
at site j is s j / s . From eq 6 and 7 one can show

where the sum is over all the binding sites: two for a 5-mer,
three for a 6-mer, and four for a 7-mer.
Now consider cutting at a base pair i which can be blocked
by drugs bound at different tetramers of a binding region. If
drug at any of the 4-mers of the binding region blocks cutting
at i, the fraction of that base pair which is free, 1 - vb, is given
by 1 - C j ( s j / s ) . However, if only drug binding at sites p and
q, say, stops cutting (because of the position of site i relative
to the binding region)

so that, in the numerator, we have 1 + DoC’Kj,with C ’ K j
being over all base pairs in the binding region for which drug
binding does not affect cutting.
Determination of the Free Drug Concentration. All the
expressions involve the free drug concentration rather than the
total drug concentration, and it is only the latter that is known
in the footprinting experiment. For an experiment with no
carrier, or an experiment with a carrier that does not bind drug,
the free drug concentration Do is obtained from the total drug
concentration D, by subtracting the concentration of drug
bound to the restriction fragment. If we consider all sites
where drug may bind (including sites for which drug binding
is monitored directly via the footprinting)
D, = Do + b
and

where Do is the free drug concentration and v b is the fraction
of site bound by drug, vb = 1 - pi. However, the situation is
complicated by the existence of overlapping binding sites. For
example, (A-T), is composed of two overlapping netropsin sites
which are each four nucleotides long. One involves base pairs
from i to i 3 while the other involves base pairs i 1 to i
4. Base pairs i 1 to i 3 are occluded by binding to either
site. On a given DNA restriction fragment only one of these
situations can occur, so that binding to one tetrameric sequence
excludes binding at the other overlapping tetrameric sequence
on the same fragment.
Although McGee and von Hippel (1974) and Epstein (1978)
have presented a treatment of such exclusion for a lattice of
identical binding sites, not all overlapping sites have the same
binding constant on the restriction fragment studied. In the
case of netropsin, the exclusion obtains for binding regions of
the type (A-T),, where n = 5-7. To treat these, let Kj be the
binding constant for a particular nucleotide position j , s be
the fragment concentration (which is also equal to the con-

+

+

+

+

b = C S=~SDoCKi/(l
i

i

+ KiDo)

(10)

assuming all sites are isolated sites. Therefore, Do can be
obtained by solving
D, = Do + sDoC

+

i

Ki

1

+ KiDo

For a binding region for which exclusion is a factor, D&/( 1
KiDo) is replaced by DO(CkKk)/(l CkKkDO).
If a carrier that binds drug (e.g., calf thymus DNA) is
present in large excess, the free drug concentration Do is largely
determined by the carrier. Let c be the carrier site concentration in base pairs. Supposing all the carrier sites to have
the same binding constant K,, we have D, = Do + cx and
CX/DO(C
- CX) = K ,
(12)

+

+

where x is the fraction of carrier site bound by drug. Since
the amount of drug bound to fragment is small compared to
the amount bound to carrier and since c is only an effective
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Table I: Equilibrium Binding Constants for Netropsin as a Function
of Sequence (XIOd M)“
carrier DNA
calf
nucleotide
Polythymus
Dosition seauence of site (dGdC’,
none
DNA
~~

46

5’-TTTA-3’
AAAT

47

5’-TTAT-3’
AATA

56

5’-TTAA-3’
AATT
5‘-TAAA-3’
ATTT

57
58
59
89
156

5’-AAAT-3’
TTTA
5’- AATT-3’
TTAA
5’-AAAT-3’
TTTA
5‘-TTAT-3‘
AATA

1.9
10
4.2

7.0
68
1.8

5.5
87
3.4

6

39

35

164

167

35

70

131

34

100

145

12

82

3.6

Table 11: Effect of Change in Base Pair Concentration on Derived
Equilibrium Constants (XlO-’ M)“
fragment concn
constant
1.5 X lod M
1 X lod M
6.67 X lo-’ M
K46
0.6
0.7
0.7
K41
8.2
6.8
5.9
KS6
0.2
0.2
0.2
K51
4.1
3.9
3.1
KS8
19.6
16.4
14.5
KS,
1.7
7.0
6.1
K09
13.5
10.0
8.2
K1S6
1.4
1.2
1.1
“The data used are from the experiment involving no carrier DNA.

14.5

“The position of the lowest numbered nucleotide of a tetramer
binding site is given.

site concentration, exclusions for sites of the type (AmT),, when
n = 5-7, need not be considered. Although one could consider
several kinds of sites on the carrier, with different binding
constants, it does not seem necessary with our present data.
The preceding discussion shows how spot intensities for
various sites can be calculated for a given total drug concentration, given values for the constants k, (one for each nucleotide where binding or enhancement are measured), Ki (one
for each four-nucleotide site where drug binding occurs), a,
and K, (if carrier, rather than the fragment, controls the free
drug concentration). We determine these constants by seeking
the values for which calculated and experimental intensities
differ as little as possible. This is done by minimizing the sum
of squared deviations as follows. Assuming a set of Ki,
we solve
eq 11 or 12 to obtain Do and b corresponding to each given
D,. Then ub is calculated for each nucleotide and each concentration. The optimum values of the kiare found by minimizing the mean-square deviation between the experimental
and calculated (eq 4) spot intensities for each base pair, assuming a value for a. We then search, using the FletcherDavidon-Powell simplex method (Fletcher, 1980), for the set
of Kiand a (and K, if necessary) which makes the sum of the
squared deviations of theoretical from experimental spot intensities as small as possible.
RESULTS
From the fitting procedure, the cleavage rate constants at
various nucleotide positions, the drug equilibrium constants,
and a redistribution constant associated with DNase I were
obtained for each experiment. In the tables given in the
supplementary material (see paragraph at end of paper regarding supplementary material), calculated and experimental
intensities are compared point by point. The equilibrium
constants are given in Table I. Some calculated plots are
compared with experimental plots in Figures 3 and 4. The
difference in plots as one goes from site to site through a
binding region, and the way in which the theoretical curves
reproduce the experimental, should be noted.
Table I shows that while the binding constants for the experiments involving no carrier DNA and calf thymus DNA
as carrier are in good agreement with each other, the values

obtained in the presence of poly(dGdC) are significantly lower
than those obtained in the former cases. However, the relative
binding constants agree for the three experiments, thus allowing establishment of the order of the affinities of the various
sites. The order found, in decreasing values of K , was (all 5’
4 3’) AAAT (58, 89) > AATT (59)
TTAT (47, 156) >
TAAA (57) > (46)
TTAA (56). Since site 156 appeared
in a poorly resolved region of the autoradiogram and the
intensity of only one band was used to monitor the loading
event, Figure 2, the value of K for this site is less certain than
the remaining values in Table I.
To determine how the concentration of the fragment would
affect the values of K for the various sites, a series of minimization calculations in which the value of the fragment
concentration was varied was carried out. The results of these
determinations for the experiment involving no carrier DNA
are given in Table 11. As is evident from the table, significant
changes in the concentration of the fragment have only a
modest effect on the value of K .

-

-

DISCUSSION
Netropsin-DNA Binding Constants. The data in Table I
reveal striking new information about the sequence dependence
of the netropsin-DNA interaction. Consideration of the sequences of the sites with the lowest binding constants, TAAA
(46, 57), TTAT (47), and TTAA (56) revealed that they
contain the dinucleotide sequence TA. As has been previously
outlined by Calladine (1982), this sequence gives rise to a
strong clash in the minor groove between adenine bases on
opposite polynucleotide strands. This clash may be relieved
by a number of mechanisms, ultimately giving rise to a local
distortion in DNA away from the idealized B form of the helix.
Since netropsin utilizes specific hydrogen bonds and van der
Waals contacts with the floor of the minor groove (Kopka et
al., 1985), the distortions produced by the TA step very likely
reduce optimal drug-DNA contact and with it the binding
constant. The tetrameric sequences having the highest binding
constants of about -lo8 M-l, AAAT ( 5 8 , 89) and AATT
( 5 9 ) , do not possess the sequence TA. These sites would be
expected to more closely conform to the B-helical structure
adopted by the AT core sequence in the duplex d(CGCGAATTCGCG)2 (Wing et al., 1980) and present optimal hydrogen bonding and van der Waals contacts toward
netropsin. Although variable-temperature footprinting studies
will be necessary to determine the contributions made by AH
and A S to the free energy of binding, recent studies suggest
that AS for the netropsin-DNA interaction may be relatively
sequence independent (Marky & Breslauer, 1987). In this
case, enthalpic effects, which have their origins in the different
structural features of the tetrameric binding sequences, would
appear to be the controlling factor in the netropsin-DNA
interaction.

QUANTITATIVE FOOTPRINTING STUDIES

The effect that flanking bases may have on the binding
constant of netropsin is difficult to discern from the data
presented in Table 1. For example, the sequence TAAA which
occurs at positions 46 and 57 possesses different flanking bases
in the two locations of the fragment. Ascertaining whether
or not these differences in the netropsin binding constants are
real, and if or to what extent flanking bases can influence
netropsin binding to a core sequence, will require additional
quantitative footprinting studies.
Although comparison of the binding constants in Table I
with values determined by other methods is not possible in most
cases, netropsin binding to the sequence AATT has recently
been studied by calorimetry (Marky & Breslauer, 1987). This
sequence, when present in the duplex d(GCGAATTCGC)2,
was found to bind netropsin with a binding constant of 2.84
X los M-l, with [Na+] = 16 mM, and d log K/d log [Na+]
of -1.55. The main cationic components in the footprinting
experiments are 10 mM Ca2+ plus Mgz+. Taking this as
equivalent to 40 mM Na+, we estimate K for our conditions
as 6.9 X lo7 M-', which is in good agreement with the values
given in Table I for the sequence AATT.
The values in Table I do not in general agree with the order
of binding affinity predicted from footprinting studies using
poly(N-methylpyrro1e)-containing peptides equipped with a
DNA cleaving agent (Youngquist & Dervan, 1985). These
studies indicated that the preference of hydrogen bonds between the three amide groups of netropsin and adjacent bases
on opposite helix strands decreases in the order AT >> AA >
TT for sites having only adenine and thymine. As is evident
from Table I, sites AATT and TTAA possess netropsin binding
constants which differ by 2 orders of magnitude. Since the
bridged-base possibilities within the sites are similar (AT, TT,
and TA for AATT; TA, AA, and AT for TTAA), it appears
that factors other than the number and type of bridged base
pairs are important in determining the affinity of the antiviral
agent. As stated earlier, structural changes in DNA, due to
adenine-adenine clashes within the minor groove, are the most
likely cause for the observed differences in the affinities associated with the AT tetramers.
Scope, Limitations, and Errors Associated with Quantitative Footprinting Analysis. A number of sources of error in
the quantitative footprinting experiment need to be considered.
Although the number of pieces of data is, in general, much
greater than the number of parameters to be calculated, there
are some cases for which constants cannot be determined
accurately. For instance, K l S 6is derived from intensity data
associated with a single band, located at position 154 on the
autoradiogram, Figure 2. Because only a single band is involved and the site is in a poorly resolved region of the autoradiogram, the determined value of K is subject to considerable
error.
The fragment concentration was not specifically determined
in the analysis. Its concentration was estimated from an initial
determination of the plasmid concentration (using optical
methods) and an assumed total recovery of the fragment in
the labeling and isolation procedures. To determine the sensitivity of the determined value of K for the various sites, trial
calculations using altered values of the fragment base pair
concentration for the experiment involving no carrier DNA
were carried out. The value assumed for all experiments, 10"
M in base pairs or 7.2 X
M in fragment concentration,
was first increased by half and then decreased by one-third.
The results, given in Table 11, show that there are only very
slight changes in equilibrium constants when the fragment
concentration is altered. The change can only be small as long
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as the maximum concentration of bound drug (fragment
concentration times number of sites per fragment which can
be occupied simultaneously) is not comparable to the total drug
concentration. This is realized for our experiments.
One should also recall that, in the studies involving calf
thymus DNA as carrier, the fragment concentration does not
directly enter into the determination of the equilibrium constants associated with the fragment. In this case, the carrier,
which is in a greater than 100-fold excess over the fragment,
controls the concentration of free drug. In the studies involving
calf thymus DNA, the concentration of strong netropsin sites
on the carrier was assumed to be
M, and the effective
binding constant K, to a site on the carrier was taken as an
additional parameter to be found in the minimization procedure. A value of K, for the carrier of 1 X lo6 M-' was found
to give the best tit between theory and experiment for the data.
In fact, only the product of K, and the number of binding sites
on the carrier is significant.
For the experiments involving poly(dGdC) as carrier, it was
assumed that no drug binding to the carrier takes place.
However, recent studies have shown that the binding constant
of netropsin toward poly(dGdC) is -5 X los M-' (Marky &
Breslauer, 1987). This value of K,, along with the fact that
the carrier concentration is about 2 orders of magnitude greater
than that of the fragment, may mean that binding to the
carrier cannot be ignored in the analysis. This would mean
that the free drug concentrations were actually lower than what
we calculated by assuming no binding to the carrier. The use
of free drug concentrations higher than the actual ones would
give low values for all of the binding constants. As Table I
indicates, the constants found from poly(dGdC) experiments
are in fact much lower than those from the other experiments.
Assuming an effective binding constant of lo5 M-' for drug
on poly(dGdC) and using the known concentration of sites on
this carrier (35 pM), we used the experimental data in a fitting
procedure to determine the binding constants for the fragment.
We indeed found binding constants of the same size as those
found from the no carrier and calf thymus DNA carrier experiments. We also attempted to use the effective binding
constant to poly(dGdC) as a variational parameter and find
the value which gave the best agreement between theoretical
and experimental data by minimizing the deviation. The
search was not successful, multiple minima being found. This
is because, for a wide range of values for the effective binding
constant, there exists a set of Ki which can produce agreement
of theoretical binding curves with our experimental data, within
the errors of the latter.
In the case of the experiments using calf thymus DNA as
carrier, the minimization algorithm converged. We did not
find solutions (sets of equilibrium binding constants Ki which
lead to minimum deviation between theoretical and experimental intensities) for which the Ki were very different from
values reported. Further, as shown in Table I, the Ki values
are in good agreement with those obtained from the no carrier
experiment. Apparently, the range of acceptable values for
K,, the effective binding constant to the carrier, is not so wide
in this case, and/or there is a small correlation between K ,
and K,, the site binding equilibrium constants to the fragment,
in this range of K,. The latter would occur, for example, if
K , were small, so as to make Dosimilar to D, for most of the
drug concentrations investigated.
The possibility that drug binding to the fragment occurs in
a cooperative manner was not addressed in the study. Unlike
numerous intercalating agents, netropsin binds without greatly
distorting the DNA helix (Kopka et al., 1985). This obser-
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vation and the fact that the initial loading events on the
139-mer are generally well separated from each other strongly
suggest that binding, at least for the strong sites, occurs in an
independent noncooperative fashion, and thus the analysis
presented here is valid.
There may also be an error connected with the correction
for enhancement (Ward et al., 1987, 1988) made according
to eq 3 in the determination of binding constants. While the
enhancement was generally small and relatively uniform over
long segments of DNA remote from drug binding, it appeared
to be 2-3 times greater at sites adjacent to a netropsin binding
site on DNA. The reason for this is unclear, but since netropsin does not greatly distort DNA, it does not appear to be
structural in origin. The presence of this effect would also
assign netropsin sites 56 and 46 a larger enhancement factor
than, for example, that of site 89 and lead to an increase in
the calculated binding constants of the weak sites at positions
46 and 56. However, the increase would be modest
so the large differences found between the values of K for these
sites and those of the strong sites appear to be due to sequence-dependent DNA structural effects rather than to artifacts associated with the enhancement.
In the analysis, seven nucleotide positions were assumed to
be equally affected by the binding of a single netropsin
molecule to DNA, except for the isolated site at 89-92, because
the footprinting plots for the region 85-92 show that site 85
exhibits partial protection by the drug which is bound at 89-92.
Thus, in this case the geometry of the enzyme may block
cleavage four base pairs to the 3r side of a drug binding site
rather than three, yielding a protection region eight nucleotides
long rather than seven. If we assume the protection region
is eight nucleotides long everywhere, we find significantly
poorer agreement between the experimental and calculated
intensities (sum of squared deviations). This is because, if the
protection region were eight nucleotides in length, the intensities for site 55 would decrease with drug concentration in
exactly the same way as for sites 57, 58, and 59, and this is
clearly not borne out by the data (see supplementary material).
Thus one must assume seven sites are protected here. These
observations suggest that the protection region may be controlled not only by the size of the drug and the geometry of
the cleavage agent but, to a certain extent, also by the sequence
at which binding is taking place.
The data for site 85 suggest that the protection is less than
that observed at sites 87, 90, and 92. This may be taken into
account by replacing eq 2 by
(rate), = k,[DNase I]p, krri[DNaseIIi(l - p i )

+

where k’: is a cleavage rate constant for a blocked site, as was
done by Brenowitz et al. (1986a). However, this would significantly increase the number of variable parameters leading
to a decrease in the significance of the values obtained.
The method described is independent of the magnitudes of
the association/dissociation rates of the ligand and the cleavage
rate of the probe (Goodisman & Dabrowiak, 1986). If the
ligand-DNA interaction is at equilibrium before the addition
of the probe and remains so during the time of the digest, the
concentrations of oligonucleotide products, after correction for
any alterations in the probe-DNA equilibrium, reflect the
fraction of a particular site which is occupied by ligand. Since
a DNA cleaving probe is being used to report the amount of
a particular site which is occupied by ligand, the possibility
exists that the probe itself shifts the ligand-DNA equilibrium
and that a competitive equilibrium is being measured. At least
for DNase I and the strong netropsin binding sites on the
fragment this does not appear to be the case. Although the

enzyme/DNA ratios were different in the calf thymus DNA
and no carrier experiments, both experiments returned the
same binding constants, indicating that the enzyme is not
disturbing the drug-DNA equilibrium.
CONCLUSIONS
In this paper we have presented the theory for quantitative
analysis of a drug-DNA footprinting experiment. The approach incorporates enhancements due to redistribution of
DNase I on DNA, as well as exclusion associated with overlapping binding sites on DNA. By use of the theory with the
autoradiographic spot intensities obtained from three sets of
footprinting experiments involving a 139 base pair restriction
fragment of pBR-322 DNA, binding constants for the antiviral
agent netropsin as a function of sequence were determined.
The analysis revealed that the presence of the dinucleotide
sequences TA within sites of the type (A-T), greatly discourages netropsin binding to DNA. This effect very likely
has its origins in a strong clash between adenines on opposite
polynucleotide strands, which produce an altered DNA
structure not optimal for netropsin binding. The scope, limitations, and errors associated with the new method were also
presented and discussed.

SUPPLEMENTARY
MATERIAL
AVAILABLE
Tables 1-111 giving the experimentally determined and
calculated concentration (areas) ai values for the various experiments (3 pages). Ordering information is given on any
current masthead page.
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ABSTRACT: The properties of the high-affinity single-stranded D N A (ssDNA) binding state of Escherichia

coli recA protein have been studied. W e find that all of the nucleoside triphosphates that are hydrolyzed
by recA protein induce a high-affinity ssDNA binding state. The effect of A T P binding to recA protein
was partially separated from the ATP hydrolytic event by substituting calcium chloride for magnesium chloride
in the binding buffer. Under these conditions, the rate of ATP hydrolysis is greatly inhibited. ATP increases
the affinity of recA protein for ssDNA in a concentration-dependent manner in the presence of both calcium
and magnesium chloride with apparent Kd values of 375 and 500 pM ATP, respectively. Under nonhydrolytic
conditions, the molar ratio of ATP to ADP has an effect on the recA protein ssDNA binding affinity. Over
an ATP/ADP molar ratio of 2-3, the affinity of recA protein for ssDNA shifts cooperatively from a lowto a high-affinity state.

%e recA protein has been shown to bind to single-stranded
DNA (ssDNA)I (McEntee et al., 1981; Silver & Fersht, 1982;
Menetski & Kowalczykowski, 1985). The affinity of recA
protein for ssDNA is influenced by the presence of ATP, ADP,
and NaCl (Menetski & Kowalczykowski, 1985). Increasing
the concentration of ADP and NaCl decreases the affinity,
while the presence of ATP increases the affinity of recA
protein for ssDNA. Weinstock et al. (1981) have shown that
recA protein can hydrolyze other nucleoside triphosphates in
addition to ATP. In this paper, we have extended our previous
analysis of the modulation of recA protein ssDNA binding
affinity by nucleotide cofactors to include those nucleotides
having significant concentrations in vivo. The data show that
all nucleotides which are hydrolyzed by recA protein induce
a high ssDNA binding affinity state similar to that induced
by ATP.
The ATP-induced high-affinity state was first observed
(Silver & Fersht, 1982) and characterized (Menetski &
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Institutes of Health (AI-18987) and an American Cancer Society Junior
Faculty research award (JFRA-70) to S.C.K. and by a predoctoral
training grant from the National Institutes of Health (GM 08061) to
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Kowalczykowski, 1985) under conditions which support the
ATPase activity of recA protein. Therefore, the data reflect
only the steady-state effect of ATP on recA protein ssDNA
binding affinity. Under these conditions, the individual effects
of binding and hydrolysis of ATP cannot be clearly separated.
Ideally, the two events could be separated under conditions
that prevent hydrolysis but not nucleotide binding. Weinstock
et al. (1981) have reported that in the presence of CaCl,, the
rate of ATP hydrolysis is less than 10% of that observed in
MgC1,. We have found that ATP is indeed bound to recA
protein in the presence of CaCl, and that ATP induces a high
ssDNA binding affinity state similar to the one observed in
MgC1,. This result shows that only ATP binding, and not
hydrolysis, is required to induce the high-affinity state. Under
conditions of reduced hydrolysis, the affinity of all recA protein
molecules for ssDNA is sensitive to the ATP/ADP molar ratio
in the buffer. As the ATP/ADP molar ratio decreases, the
I Abbreviations: etheno M13 DNA, modified ssDNA containing
1,N6-ethenoadenosine and 3,N4-ethenocytosine; ssDNA, single-stranded
DNA; dsDNA, double-stranded DNA; ATPyS, adenosine 5’-0-(3-thiotriphosphate); poly(dA), poly(deoxyadeny1ic acid); RFI, relative
fluorescence increase; Tris-HCI, tris(hydroxymethy1)aminomethane hydrochloride; SSB protein, E . coli single-stranded DNA binding protein.
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